- Home
- PHAT vs SBGI Comparison
PHAT vs SBGI Comparison
Compare PHAT & SBGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- SBGI
- Stock Information
- Founded
- PHAT 2018
- SBGI 1986
- Country
- PHAT United States
- SBGI United States
- Employees
- PHAT N/A
- SBGI N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- SBGI Broadcasting
- Sector
- PHAT Health Care
- SBGI Industrials
- Exchange
- PHAT Nasdaq
- SBGI Nasdaq
- Market Cap
- PHAT 820.8M
- SBGI 956.9M
- IPO Year
- PHAT 2019
- SBGI 1995
- Fundamental
- Price
- PHAT $11.66
- SBGI $13.95
- Analyst Decision
- PHAT Strong Buy
- SBGI Buy
- Analyst Count
- PHAT 5
- SBGI 6
- Target Price
- PHAT $16.40
- SBGI $20.08
- AVG Volume (30 Days)
- PHAT 1.1M
- SBGI 435.2K
- Earning Date
- PHAT 11-06-2025
- SBGI 11-05-2025
- Dividend Yield
- PHAT N/A
- SBGI 7.46%
- EPS Growth
- PHAT N/A
- SBGI N/A
- EPS
- PHAT N/A
- SBGI 0.74
- Revenue
- PHAT $114,039,000.00
- SBGI $3,481,000,000.00
- Revenue This Year
- PHAT $207.52
- SBGI N/A
- Revenue Next Year
- PHAT $96.46
- SBGI $9.52
- P/E Ratio
- PHAT N/A
- SBGI $18.08
- Revenue Growth
- PHAT 1049.82
- SBGI 8.11
- 52 Week Low
- PHAT $2.21
- SBGI $11.89
- 52 Week High
- PHAT $19.71
- SBGI $18.46
- Technical
- Relative Strength Index (RSI)
- PHAT 54.88
- SBGI 49.74
- Support Level
- PHAT $11.89
- SBGI $13.19
- Resistance Level
- PHAT $13.00
- SBGI $14.37
- Average True Range (ATR)
- PHAT 0.71
- SBGI 0.38
- MACD
- PHAT -0.11
- SBGI -0.03
- Stochastic Oscillator
- PHAT 26.57
- SBGI 55.33
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About SBGI Sinclair Inc.
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.